Meanwhile, some clinical studies have mentioned that co-mutations of TP53 and PI3K/AKT/mTOR pathway are associated with primary resistance to HER2-targeted therapy in lung adenocarcinomas [297]. The gene discussed is ERBB2; the disease is lung adenocarcinoma.